Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Shiga Toxin-Producing E. coli Directly Detected from Stool

By LabMedica International staff writers
Posted on 06 Nov 2012
A rapid diagnostic can detect the potentially fatal Shiga toxin-producing Escherichia coli (STEC), directly from a stool specimen.

The test offers significant advantages over other rapid cassette assays in that it removes the need for overnight bacterial culture preparation. More...
The Shiga Toxin Quik Chek provides results up to 24 hours before other rapid tests, enabling clinicians to initiate patient care sooner and minimize the potential for broader bacterial outbreaks. The test’s considerably shorter sample preparation process also helps to simplify laboratory workflows.

Alere Inc., (Waltham, MA, USA) received confirmation that the US Food and Drug Administration (FDA; Silver Spring, MD, USA) has cleared the TECHLAB (Blacksburg, VA, USA) Shiga Toxin Quik Chek test for the US market.

“The recent FDA clearance of our new Shiga Toxin E. coli test enhances Alere’s position as a market leader for enteric disease diagnostics and is a testament to our strong partnership with TECHLAB, Inc.,” said Jim Post, president of Alere North America. “By narrowing the diagnostic window from a day to 30 minutes, the Shiga Toxin Quik Chek promises to be a significant help to clinicians, facilitating more rapid patient care that leads to better outcomes, improving workflows, and reducing the potential for broader outbreaks.”

The Shiga Toxin Quik Chek is the newest addition to the Alere Enterics suite of Quik Chek assays developed and manufactured by TECHLAB, Inc. It combines the accuracy of an enzyme immunoassay with the speed and ease of use of a cassette. The Shiga Toxin Quik Chek requires few processing steps and provides differentiated results for Shiga Toxin 1 and 2 within 30 minutes of sample receipt, allowing for rapid diagnosis and prompt initiation of patient treatment.

Alere holds a 49% interest in TECHLAB, Inc. and has exclusive global distribution rights to the company’s line of enteric diagnostics. In addition to being cleared for use in the United States, the Shiga Toxin Quik Chek is CE marked and available in other worldwide markets.

Shiga toxin-producing E. coli are commonly associated with food- and water-borne outbreaks of diarrheal illness, and diagnostics for these bacteria account for approximately USD 16 million of the total enteric disease market. Shiga Toxin 1 and Shiga Toxin 2, produced singly or in combination by more than 200 different strains of STEC, are the enterohemorrhagic toxins that cause disease. O157 is the most well-known strain and has been responsible for numerous outbreaks in the past. Shiga Toxin Quik Chek detects toxins from both O157 and non-O157 strains of E. coli.

Related Links:
Alere
TECHLAB




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.